News & Views - Telix Pharmaceuticals Limited | Telix Pharmaceuticals Limited

Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM

Telix today announces that 20 company-related abstracts will be presented at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Vienna, Austria from October 17-21, 2026.

Telix to Host Capital Markets Day in Melbourne on November 4, 2026

Telix today advises that it will host advises that it will host a Capital Markets Day in Melbourne, Australia, on Wednesday, November 4, 2026, from 9:00 a.m. to 12:30 p.m. (AEDT).

First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)

Telix today announces that the first patients in the United States (U.S.) have been dosed with Pixclara® (floretyrosine F 18 or 18F-FET), its FDA-approved, amino acid positron emission tomography (PET) drug for glioma (brain cancer) imaging.

Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging

Telix today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s BiPASS® program, evaluating gallium-68 (68Ga) PSMA-PET imaging in combination with MRI for the detection of prostate cancer prior to biopsy.

Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse

Telix today announces it has signed a strategic agreement to combine with ITM Isotope Technologies Munich SE (“ITM”), a global leader in radioisotope production and radiopharmaceutical development.

“Let’s go, let’s get them”

Michael Ramos served for 16 years as the elected District Attorney of San Bernardino County, California. In 2017, a year before he planned to retire, he was diagnosed with prostate cancer. We spoke with him about his diagnosis, the scan that changed the course of his care, and why he now brings a prosecutor’s energy to patient advocacy.

FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara

Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Pixclara® (floretyrosine F 18 or 18F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer).

Reliable access and availability of Ga-68 radiopharmaceuticals

There when you need it: we asked five leaders across the nuclear medicine industry to share their specific experiences with one of the four key advantages of Gallium-68* (Ga-68) PET imaging: availability and reliable access on demand.

Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference

Telix advises that Dr. Christian Behrenbruch, Managing Director and Group CEO and Kevin Richardson, CEO, Precision Medicine will present at the upcoming Morgan Stanley 24th Annual Global Healthcare Conference and at the H.C. Wainwright 28th Annual Global Investment Conference, both in New York, NY.

Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway

Telix today announced completion of patient enrollment in the Phase 3 BiPASS™ study of its commercial PSMA-PET[1] imaging agents, Illuccix® (kit for the preparation of gallium Ga68 gozetotide injection) and Gozellix® (kit for the preparation of gallium Ga68 gozetotide injection) for prostate cancer imaging in the pre-biopsy setting. Telix has also aligned with the United States (U.S.) Food and Drug Administration (FDA) on a New Drug Application (NDA) pathway for BiPASS that, if approved, would support reimbursement as a new product and broaden patient access.